Medicine and Dentistry
Adjuvant Therapy
9%
Brain Metastasis
5%
Cancer
7%
Cancer Cell
13%
Cancer Research
11%
Clear Cell
12%
Clear Cell Renal Cell Carcinoma
55%
Clinical Trial
32%
Clinician
10%
Combination Therapy
9%
Continuing Medical Education
7%
COVID-19
9%
Disease
27%
Germ Cell Cancer
9%
Germinoma
13%
Hazard Ratio
13%
High Dose Chemotherapy
5%
High Risk Population
10%
Immune Checkpoint Inhibitor
11%
Immunoglobulin
11%
Immunotherapy
6%
Kidney Cancer
34%
Kidney Metastasis
100%
Kidney Tumour
8%
Lymph Node Metastasis
5%
Malignant Neoplasm
16%
Medical Oncology
9%
Metastatic Carcinoma
7%
Neoplasm
14%
Nephrectomy
18%
Oncologist
17%
Oncology
16%
Overall Survival
61%
Papillary Renal Cell Carcinomas
9%
Paraneoplastic Syndrome
9%
Pazopanib
13%
Prognostic Factor
7%
Progression Free Survival
20%
Prostate Cancer
6%
Retroperitoneal Lymph Node Dissection
7%
Sarcomatoid
6%
Sunitinib
6%
Surgery
14%
Targeted Therapy
71%
Testis Cancer
18%
Treatment Duration
10%
Urologist
5%
Urology
8%
Vasculotropin
32%
Vasculotropin Inhibitor
9%
Keyphrases
Academic Center
5%
Canada
10%
Chemotherapy
9%
Clinical Outcomes
13%
Clinical Trials
15%
Combination Therapy
9%
Confidence Interval
6%
Disease Control Rate
5%
Favorable Intermediate Risk
5%
First-line Therapy
7%
Genitourinary Malignancies
6%
Germ Cell Tumor
12%
Immune Checkpoint Inhibitor Therapy
9%
Immune Checkpoint Inhibitors
6%
Immuno-oncology Agents
5%
International Metastatic Renal Cell Carcinoma Database Consortium
19%
Ipilimumab
7%
Kidney Cancer
18%
Locally Advanced Renal Cell Carcinoma
9%
Medical Oncologist
12%
Metastatic RCC
7%
Metastatic Renal Cell Carcinoma (mRCC)
58%
Nephrectomy
6%
Nivolumab
7%
Oncological Outcomes
5%
Overall Survival
27%
Paraneoplastic Syndrome
9%
Population-based
5%
Post-chemotherapy
5%
Practice Patterns
5%
Priority Setting Partnership
5%
Prognostic Groups
9%
Progression-free Survival
14%
Progressive Disease
5%
Quality Indicators
6%
Renal Cell Carcinoma
13%
Renal Tumor
6%
Resection
5%
Surgical Management
5%
Survival Outcomes
5%
Targeted Therapy
38%
Testis Cancer
9%
Tumor
6%
Urologists
5%
Vascular Endothelial Growth Factor
9%
Pharmacology, Toxicology and Pharmaceutical Science
Axitinib
5%
Clinical Trial
16%
Disease
17%
Disease Free Survival
9%
Everolimus
5%
Immune Checkpoint Inhibitor
9%
Ipilimumab
6%
Kidney Cancer
14%
Kidney Metastasis
94%
Lymph Node Metastasis
5%
Malignant Neoplasm
9%
Nivolumab
6%
Overall Survival
62%
Pazopanib
17%
Phase II Trials
9%
Placebo
13%
Progression Free Survival
25%
Protein Tyrosine Kinase
6%
Protein Tyrosine Kinase Inhibitor
9%
Renal Cell Carcinoma
55%
Sorafenib
5%
Sunitinib
23%
Vasculotropin
28%
Vasculotropin Inhibitor
9%
Vasculotropin Receptor
6%